Elisa M. Rodriguez was named chief diversity and equity officer for faculty at Roswell Park Comprehensive Cancer Center.
Pediatric oncologist A. Thomas Look, of the Dana-Farber Cancer Institute, was named the 2021 recipient of The Society of Memorial Sloan Kettering Prize.
The American Association for Cancer Research has announced its newest class of grant recipients.
The American Association for Cancer Research plans to provide a workshop on excellence in clinical trial implementation as part of the Bristol Myers Squibb Foundation Diversity in Clinical Trials Career Development Program.
Seventy one NCI-designated cancer centers and partner organizations have issued a joint statement urging the nation’s physicians, parents, and young adults to get the human papillomavirus vaccination back on track.
A new initiative, Project Health Equality, aims to address the structural and cultural barriers that prevent Black and Hispanic women in the U.S. from receiving the same quality health care as white women.
Imugene Ltd. and City of Hope have entered into a licensing agreement for the patents covering a novel combination immunotherapy.
FDA has approved Opdivo (nivolumab) for patients with completely resected esophageal or gastroesophageal junction cancer with residual pathologic disease who have received neoadjuvant chemoradiotherapy.
FDA’s Oncology Center of Excellence launched the “Send Your Oncology Research Questions to FDA” crowdsourcing challenge. OCE is using this challenge to provide an opportunity for interested stakeholders to submit ideas for research using pooled analyses of oncologic clinical trial data directly to FDA’s scientific staff.
Clinical trials for oncology drugs are running into unique challenges as protocols become more complex and as the number of new investigational agents continues to outpace all other drugs, according to a recent study by Tufts University researchers.
